<DOC>
	<DOC>NCT02063230</DOC>
	<brief_summary>A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.</brief_summary>
	<brief_title>To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects</brief_title>
	<detailed_description>An open label study to assess the pharmcokinetics, safety and tolerability of a single dose of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Inclusion Criteria for all participants: 1. Subjects will be males or females (nonchildbearing potential) aged 18 years or more and with a weight of at least 45 kg and a BMI between 18 and 40 kg/m2 inclusive. Inclusion Critera only for hepatic impaired patients: 2. Subjects with stable liver cirrhosis and hepatic impairment for at least 3 months prior to the start of the study. Inclusion Criteria only for healthy volunteers: 3. Subjects must be in good health, as determined by a medical history, physical examination, 12lead ECG, clinical laboratory evaluations, and an ophthalmic examination performed before the administration of the investigational product. Exclusion Criteria for all participants: 1. Subjects of Japanese or nonJapanese Asian ethnicity 2. Any one parent or grandparent (maternal or paternal) is Japanese or nonJapanese Asian (eg, China, Taiwan, Korea, Philippines, Thailand, Vietnam, and Malaysia). Asian Indians are acceptable. 3. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of the investigational product 4. Subjects who smoke more than 10 cigarettes or the equivalent in tobacco per day. Exclusion criteria for hepatic impaired patients only 5. Undergone liver transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Phase I, healthy, pharmacokinetic, hepatic impairment</keyword>
</DOC>